At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 145 enrolled
Drug / intervention
KPL-404 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
In Brief
A Phase 2 clinical trial evaluating KPL-404 and Placebo for Arthritis, Rheumatoid. Completed, enrolled 145 participants across 42 sites in 7 countries.
Detailed Summary
Phase 2 study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KPL-404 in subjects with moderate to severe Rheumatoid Arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesBulgaria, Czechia, Georgia, Hungary, Poland, South Africa, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartDec 2021
First PostedJan 2022
Primary CompletionFeb 2024
Study CompletionMay 2024
TodayJul 2026
First PostedJan 20, 2022
Enrollment StartDec 14, 2021
Primary CompletionFeb 8, 2024
Study CompletionMay 6, 2024
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 4.5 years ago
Interventions
KPL-404drug
Humanized monoclonal antibody
Placebodrug
Matching placebo